This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Review of the current targeted therapies for non-small-cell lung cancer
Kim-Son H Nguyen, Joel W Neal, Heather Wakelee
Kim-Son H Nguyen, Joel W Neal, Heather Wakelee, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States
ORCID number: $[AuthorORCIDs]
Author contributions: All authors contributed equally to this paper.
Correspondence to: Heather Wakelee, MD, Division of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, CA 94305, United States. firstname.lastname@example.org
Telephone: +1-650-7367221 Fax: +1-650-7243697
Received: February 10, 2014 Revised: May 7, 2014 Accepted: May 28, 2014 Published online: October 10, 2014
The last decade has witnessed the development of oncogene-directed targeted therapies that have significantly changed the treatment of non-small-cell lung cancer (NSCLC). In this paper we review the data demonstrating efficacy of gefitinib, erlotinib, and afatinib, which target the epidermal growth factor receptor (EGFR), and crizotinib which targets anaplastic lymphoma kinase (ALK). We discuss the challenge of acquired resistance to these small-molecular tyrosine kinase inhibitors and review promising agents which may overcome resistance, including the EGFR T790M-targeted agents CO-1686 and AZD9291, and the ALK-targeted agents ceritinib (LDK378), AP26113, alectinib (CH/RO5424802), and others. Emerging therapies directed against other driver oncogenes in NSCLC including ROS1, HER2, and BRAF are covered as well. The identification of specific molecular targets in a significant fraction of NSCLC has led to the personalized deployment of many effective targeted therapies, with more to come.
Core tip: The development of oncogene-directed targeted therapies has significantly changed the treatment of non-small-cell lung cancer. We review the data demonstrating efficacy of small-molecule tyrosine kinase inhibitors against epidermal growth factor receptor, anaplastic lymphoma kinase, ROS1, and other oncogenes. We also discuss the challenge of acquired resistance to these therapies and review promising agents which may overcome resistance.
Citation: Nguyen KSH, Neal JW, Wakelee H. Review of the current targeted therapies for non-small-cell lung cancer. World J Clin Oncol 2014; 5(4): 576-587
Lung cancer is the leading cause of cancer-related deaths around the world with approximately 1.3 million deaths per year and a poor prognosis for those with advanced stage disease treated with traditional chemotherapy agents[1,2]. However, the last decade has witnessed the discovery of molecular changes that drive lung cancer in a substantial minority of patients and development of many targeted therapies that have significantly changed treatment in this setting. In this paper we review the data leading to approval of targeted therapies against the epidermal growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK), discussing the challenges of overcoming acquired resistance to these small-molecular tyrosine kinase inhibitors (TKIs). We also review several other promising targeted therapies currently in development.
FIRST-GENERATION EGFR TKIS
The first available targeted therapies for advanced NSCLC were gefitinib and erlotinib, both of which are small-molecule TKIs against EGFR, also known as HER1 or ErbB-1. The dimerization of EGFR activates its tyrosine kinase, which in turn activates intracellular signal transduction pathways involved in many cellular processes. Early work on EGFR in lung cancer has shown that EGFR overexpression is commonly seen in NSCLC[3,4], motivating the development of EGFR TKIs.
Phase II studies of gefitinib and erlotinib in the second- or third-line setting for advanced NSCLC in unselected patients were promising, showing a partial radiographic response rate of about 12% with symptomatic improvements[5-7]. The first clinical trial to show an improved overall survival (OS) was the Canadian phase III BR.21 trial, which randomized patients with stage IIIB or IV NSCLC, neither clinically nor molecularly selected for EGFR mutations, who had received one or two chemotherapy regimens, to either erlotinib or placebo. Patients receiving erlotinib had a median OS of 6.7 mo, compared with 4.7 mo for those on placebo. Interestingly, a similar phase III study, the Iressa Survival Evaluation in Lung Cancer (ISEL) trial, comparing gefitinib to placebo in the second- or third-line setting failed to demonstrate an improved OS. However, subgroups of never smokers and Asians did have statistically significant survival advantage on gefitinib compared to placebo. That erlotinib apparently had greater efficacy than erlotinib might be due to the fact that erlotinib was dosed at its maximum tolerated dose (MTD) while gefitinib was dosed at one-third of its MTD.
However, data from these clinical trials and others suggested that EGFR immunohistochemical staining intensity was not predictive of therapeutic benefit. Subsequently, somatic activating EGFR mutations, most commonly including exon 19 deletions and exon 21 L858R missense mutations, were discovered to be a dominant predictor of responsiveness to EGFR TKIs[10-15]. It is estimated that these activating EGFR mutations are present in tumors from about 50% of Asian patients with NSCLC and 15% of Western patients[16-19]. The cause for this difference in the prevalence rates of EGFR mutations among various ethnic groups remains unknown, yet EGFR mutations are also observed most frequently in women, patients with no or minimal history of smoking, and tumors of adenocarcinoma histology[16,17,20].
More recent first line studies in advanced NSCLC attempted to enrich patients with activating EGFR mutations to compare EGFR TKI therapy with conventional chemotherapy. The pivotal Iressa Pan-Asia Study (IPASS) randomized over 1200 untreated patients who were never smokers or former light smokers to either gefitinib or the combination of carboplatin and paclitaxel. The progression-free survival (PFS) at 12 mo was 25% for gefitinib and 7% for chemotherapy. For patients with activating EGFR mutations, gefitinib was associated with a hazard ratio for progression of 0.48 (P < 0.001) compared to chemotherapy, while for patients who were negative for EGFR mutations, gefitinib was associated with shorter PFS with a hazard ratio for progression of 2.985 (P < 0.001). OS was similar between the two groups, presumably due to crossover[18,19]. Similar results have been observed in other trials involving gefitinib conducted in Asia. The First-SIGNAL trial from the South Korea comparing gefitinib to cisplatin and gemcitabine in the first-line setting for advanced pulmonary adenocarcinoma in never smokers demonstrated a PFS benefit for gefitinib but also no OS difference. This study also had significant crossover. For the subgroup of patients with EGFR-mutant adenocarcinoma, gefitinib was associated with a higher overall response rate (ORR) (84.6% vs 37.5%; P = 0.002) and a trend toward longer PFS (HR = 0.544; 95%CI: 0.269-1.100; P = 0.086) compared to chemotherapy. For those patients with tumors harboring wild-type EGFR, the reverse was found: chemotherapy showed a trend toward higher ORR and longer PFS. Together, the IPASS and First-SIGNAL studies demonstrated that activating EGFR mutations are predictors of benefit with gefitinib and that wild-type EGFR patients do poorly with first-line gefitinib compared to platinum-based chemotherapy.
Instead of selecting patients by smoking status, subsequent studies included only patients with activating EGFR mutations. In randomized controlled trials, Japanese researchers confirmed the PFS superiority of gefitinib to chemotherapy as first-line treatment for patients with advanced EGFR-mutant NSCLC. In the West Japan Thoracic Oncology Group trial 3405, patients on the gefitinib arm had a median PFS of 9.6 mo, compared to 6.6 mo for those on cisplatin plus docetaxel[22,23]. In a North-East Japan Study Group trial, gefitinib was associated with a PFS of 10.8 mo vs 5.4 mo for carboplatin-paclitaxel. In both Japanese trials, the differences in OS were not statistically significant[23,24].
Similar to gefitinib, erlotinib has also demonstrated PFS advantages compared to chemotherapy in patients with EGFR-mutant NSCLC in the first-line setting. The Chinese OPTIMAL trial showed a PFS of 13.1 mo for erlotinib vs 4.6 mo for carboplatin and gemcitabine. The EURTAC trial demonstrated that EGFR TKIs were also effective for European patients with EGFR-mutant NSCLC in the first-line setting. In this study, patients receiving erlotinib had a PFS of 9.7 mo, compared to 5.2 mo for those receiving a platinum-based chemotherapy regimen. OS was not statistically different between the erlotinib and chemotherapy arms in either the OPTIMAL or EURTAC trial[26,27].
More recent efforts have focused on newer-generation EGFR TKIs. Afatinib is an irreversible ErbB family inhibitor that, in preclinical models, has been shown to have activity against activating EGFR mutations as well as the EGFR T790M mutation that confers resistance to erlotinib and gefitinib. The initial randomized studies of afatinib addressed its efficacy in the EGFR-TKI resistance setting. In LUX-Lung 1, patients with EGFR-mutant NSCLC who had received a first-generation EGFR TKI and chemotherapy were randomized to either afatinib or placebo. PFS was 3.3 mo for afatinib, compared to 1.1 mo for placebo (P < 0.0001). The drug was then studied as a first-line treatment for EGFR-mutant NSCLC. The global LUX-Lung 3 phase III study randomized 345 patients to either afatinib or cisplatin-pemetrexed. The median PFS was 11.1 mo for afatinib and 6.9 mo for chemotherapy (HR = 0.58; 95%CI: 0.43-0.78; P = 0.001). Similarly, the LUX-Lung 6 phase III study randomized 364 Chinese patients with EGFR-mutant NSCLC to either afatinib or cisplatin-gemcitabine in a 2 to 1 ratio. The median PFS of patients on the afatinib arm was 11.0 mo vs 5.6 mo for chemotherapy, HR = 0.28, P < 0.0001. In July 2013, nine years after the initial approval of erlotinib for treatment of advanced NSCLC (second or third line, regardless of EGFR mutation status) and only two months after the approval of erlotinib for first-line treatment of advanced EGFR-mutant NSCLC, the United States Food and Drug Administration (FDA) approved afatinib, for the first-line treatment of advanced NSCLC with activating exon 19 deletions and L858R EGFR mutations. A pooled subgroup analysis from trials of afatinib in TKI-naïve patients demonstrated good activity with a PFS of 10.7 mo in patients with other EGFR mutations that are classically sensitive to erlotinib, like L861Q and G719X. However, tumors initially harboring historically TKI-resistant alterations including T790M and exon 20 insertions appear markedly less sensitive, with PFS of under 3 mo in both groups. The ongoing clinical trial LUX-Lung 7 is comparing afatinib against gefitinib in the first-line setting for EGFR-mutant NSCLC to help determine relative efficacy of the two TKIs (ClinicalTrials.gov identifier: NCT01466660).
OVERCOMING RESISTANCE TO EGFR TYROSINE KINASE INHIBITORS
The discovery of EGFR TKIs has thus revolutionized treatment of NSCLC with activating EGFR mutations, with erlotinib, gefitinib, and afatinib approved for use in various countries. While a small minority of patients have disease control for years on these drugs, on average these TKIs have a median response duration seldom exceeding one year due to acquired resistance. The mechanisms of resistance vary, with the EGFR T790M point mutation in exon 20 being the most common cause of acquired resistance, accounting for about 50% of cases. The T790M “gatekeeper” mutation was initially thought to simply exclude binding of EGFR-TKI drugs by steric hindrance, but more importantly it appears to restore the EGFR affinity for ATP, thus decreasing the binding of the ATP-competitive TKIs[33-35]. There is increasing evidence that a low level of the T790M mutation exists before treatment in many patients with EGFR-mutant NSCLC and predicts a worse PFS on erlotinib compared to those without pre-treatment T790M. Another clearly described cause of acquired resistance to TKI is the amplification of the mesenchymal epithelial transition (MET) proto-oncogene, which activates an AKT-mediated signaling pathway, bypassing EGFR[37,38]. Several other EGFR mutations have also been implicated in conferring resistance to EGFR TKIs: D761Y, T854A, and L747S, in addition to activating BRAF mutations and HER2 amplification. Interestingly, some TKI-resistant tumors undergo histologic changes, including transformation from non-small-cell to small cell or epithelial-mesenchymal transition, leading to resistance through less direct mechanisms.
Since half of acquired resistance is dependent on the T790M missense mutation, newer EGFR TKIs are in development to overcome resistance. The second-generation inhibitors afatinib and dacomitinib irreversibly inhibit both wild-type and mutant EGFR proteins, and to a lesser extent, T790M EGFR. In clinical trials designed to test activity in patients with acquired resistance, however, these drugs have not routinely induced reliable, robust responses. In the LUX-Lung 4 single-arm phase II study from Japan, patients were enrolled with EGFR-mutant NSCLC that had progressed on gefitinib/erlotinib and chemotherapy. Treatment with afatinib was associated with a modest response rate of 8.2%, and median PFS of 4.4 mo with median OS of 19.0 mo. Similarly, the larger placebo controlled trial of LUX-Lung 1 trial of afatinib after failure of chemotherapy and erlotinib or gefitinib evaluated 390 patients on afatinib and 195 patients on placebo. Compared with the afatinib group, the placebo group had an identical OS (10.8 mo vs 12.0 mo; HR 1.08; 95%CI: 0.86-1.35; P = 0.74). However, median PFS was statistically better in the afatinib group (3.3 mo vs 1.1 mo; HR 0.38; 95%CI: 0.31-0.48; P < 0.0001), yet the response rate was still unimpressive in this group (7%). Dacomitinib (PF-00299804) is another irreversible TKI active against EGFR, HER2, and HER4. In a preliminary report of a phase II studying patients with NSCLC after failure of chemotherapy and erlotinib, responses were seen in 3 of 62 evaluable patients (5%). To confirm the activity in this population, a large phase III study, the Canadian BR.26 trial, randomized 720 patients to dacomitinib or placebo for progressive disease after treatment with chemotherapy and an EGFR TKI (ClinicalTrials.gov identifier NCT01000025). According to a recent press release, however, this trial failed to meet its primary objective of prolonging overall survival vs placebo, with results to be reported in upcoming meetings. Another phase III study comparing dacomitinib vs gefitinib in treatment-naive patients with EGFR-mutant NSCLC is still ongoing (ClinicalTrials.gov identifier NCT01774721). With other second-generation EGFR inhibitors including neratinib and XL647 (which also inhibits VEGFR), similarly low response rates were reported in trials of acquired resistance.
The strategy of combination therapy incorporating second-generation inhibitors has also been employed with mixed success. Cetuximab, a monoclonal antibody against EGFR, adds little activity when added to erlotinib in the setting of acquired resistance. However, the combination of afatinib and cetuximab is surprisingly effective for acquired resistance. In a phase Ib study, patients with acquired EGFR inhibitor resistance were given 40 mg daily of afatinib plus 500 mg/m2 of cetuximab every other week. Of 61 reported patients at the recommended dose, 35% had confirmed response and 95% had stable disease or better, including patients with tumors with and without T790M mutations. Side effects including rash, diarrhea, and mucositis were significant. Follow-up trials of these agents for patients with EGFR-mutant NSCLC are currently in development. The strategy of combined EGFR and MET inhibition has also been employed in phase I/II trials. In a dose-finding trial of erlotinib plus the MET and VEGFR inhibitor cabozantinib (XL-184), 53 patients were evaluable and had a response rate of 8%. Interestingly, the two patients with confirmed MET copy number gain had disease shrinkage. Preliminary results from a phase I study using dacomitinib plus crizotinib (a MET and ALK inhibitor) noted a response rate of 5% in 20 patients who had previously had response or prolonged stable disease on an EGFR TKI. Further study of the infrequent MET amplification cohort will be of interest using this combination.
Although the second-generation agents do not appear to effectively combat acquired resistance, a novel class of third-generation EGFR inhibitors has been recently identified that much more potently inhibits mutant EGFR with T790M than wild type EGFR. The first such described molecules demonstrated impressive preclinical effectiveness in a mouse model of T790M-dependent acquired EGFR resistance. Since that time, two compounds with similar affinity for mutant, including T790M, EGFR protein, but minimal binding of wild-type EGFR, have early phase I results reported: CO-1686 and AZD9291. In a preliminary report of the CO-1686 clinical trial, 56 patients with EGFR activating mutations and failure of prior EGFR TKI therapy have been enrolled to a dose escalation trial. Of the 9 patients with tumors testing positive for T790M who were treated at the highest dose, 6 responded, 2 had stable disease (with slight decrease), and 1 patient progressed on therapy. In a similarly designed dose escalation study of AZD9291, 35 patients were treated with doses ranging from 20-80 mg. Fifteen of 35 patients (43%) had a confirmed or unconfirmed partial response, including those with and without documented T790M mutation. The majority of patients had some degree of tumor control, and only 4 patients progressed initially on treatment. Interestingly, wild-type EGFR toxicity for both agents appears quite mild, with rash and diarrhea infrequently reported.
FIRST-GENERATION ALK TKI
Activating EGFR mutations are not the only actionable genetic alterations in NSCLC. In 2007, Japanese researchers working with NSCLC cells discovered an inversion in chromosome 2p resulting in a novel fusion gene comprised of portions of the echinoderm microtubule-associated protein-like 4 (EML4) gene and the anaplastic lymphoma kinase (ALK) gene, including its entire intracellular tyrosine kinase domain. The EML4 fusion partner mediates ligand-independent dimerization of ALK, leading to constitutive kinase activity. EML4-ALK fusion protein was tumorigenic in mice, and the Japanese researchers detected this transcript in about 5 out of 75 (6.7%) tumors from NSCLC patients. Subsequent published series have suggested that the frequency of ALK gene rearrangement in unselected NSCLC patients is about 3% to 6%[58-63]. Besides EML4, several other fusion partners of ALK, e.g., KIF5B and TFG, have been identified[64,65]. Similar to activating EGFR mutations, ALK gene rearrangements are associated with younger age, never or light smoking status, and adenocarcinoma histology; however there is equal distribution by sex[66,67].
Crizotinib, an oral, small-molecule inhibitor of ALK and c-Met, was originally developed as a potential therapeutic agent for ALK-positive anaplastic large cell lymphoma (ALCL). The drug has indeed demonstrated activity in ALK-positive ALCL as well as ALK-positive diffuse large B cell lymphoma and inflammatory myofibroblastic tumors[70,71]. However, crizotinib has been most widely applied in the treatment of NSCLC with ALK gene rearrangements after marked activity was noted in the patient population in the phase I trial, leading to FDA approval of the drug. In a phase III study, 347 patients with locally advanced or metastatic ALK-rearranged NSCLC who had received one prior platinum-based regimen were randomized to crizotinib or chemotherapy with either pemetrexed or docetaxel. The median PFS was 7.7 mo in the crizotinib group, significantly superior to the 3.0 mo in the chemotherapy group (HR for progression or death with crizotinib, 0.49; 95%CI: 0.37-0.64; P < 0.001). Common adverse events associated with crizotinib were visual disorders, nausea, diarrhea, vomiting, constipation, and elevated liver enzymes. Rare cases of esophageal ulceration associated with crizotinib have also been reported. In August 2011, only four years after the discovery of ALK gene rearrangements in NSCLC, the FDA granted accelerated approval to crizotinib for patients with ALK-positive NSCLC. An ongoing clinical trial seeks to demonstrate superiority of crizotinib compared to first-line platinum/pemetrexed chemotherapy for ALK-rearranged (ClinicalTrials.gov identifiers: NCT01154140 and NCT01639001). Accrual is complete and results are awaited, though crizotinib is commonly used in the first line setting without this evidence.
OVERCOMING RESISTANCE TO CRIZOTINIB
Unfortunately, many tumors with ALK gene rearrangements eventually acquire resistance to crizotinib, frequently within one year, similar to EGFR-mutant NSCLC developing resistance to erlotinib or gefitinib. Researchers from Massachusetts General Hospital and collaborators analyzed 18 patients with crizotinib-resistant NSCLC and discovered that almost one-quarter of the patients had either secondary mutations in the ALK tyrosine kinase domain or ALK fusion gene amplification. About half of the patients were found to have tyrosine kinase activity via EGFR or KIT, thus bypassing the inhibited ALK-mediated pathway. The L1196M mutation has been shown to be a gatekeeper mutation in the ALK kinase domain, conferring resistance to crizotinib[76-79], similar to the EGFR T790M mutation that confers resistance to erlotinib. Besides EGFR mutations[76,78], KRAS mutations have also been identified as a possible mechanism of crizotinib resistance in a separate series of crizotinib-resistant patients from the University of Colorado.
Multiple second-generation ALK inhibitors have been developed with increased potency and potential to overcome acquired resistance to crizotinib, including ceritinib (LDK378), AP26113, and alectinib (CH/RO5424802). Ceritinib has recently been shown to have efficacy against crizotinib-naive as well as crizotinib-resistant ALK-positive lung cancer. In a multicenter phase I study, 131 patients with advanced malignancies harboring a genetic alteration in ALK, including 123 patients with ALK-rearranged NSCLC, received ceritinib orally at doses of 50 mg to 750 mg once daily. Among the 88 NSCLC patients who received ceritinib at 400-750 mg daily, the ORR was 70%. In the subset of 64 crizotinib-resistant patients, the ORR was similar at 73%, with responses observed in patients with different crizotinib resistance mutations, patients without detectable mutation, and even patients with untreated CNS metastases. In all 123 NSCLC patients, the median PFS was 8.6 mo (95%CI: 4.3-19.3). Ceritinib appeared to have more toxicities than crizotinib, however, with the most common adverse events, including all grades, being nausea (72%), diarrhea (69%), vomiting (50%), and fatigue (31%). The drug has advanced to phase III clinical trials, being compared vs chemotherapy for ALK-rearranged NSCLC in the first-line setting (ClinicalTrials.gov identifier NCT01828099) or in the third-line setting for patients previously treated with chemotherapy and crizotinib (ClinicalTrials.gov identifier NCT01828112).
Another promising second-generation ALK inhibitor is AP26113, which exhibits activity against all 9 clinically-identified crizotinib-resistant mutants, including the L1196M gatekeeper, in preclinical experiments[81,82]. Like most other ALK inhibitors, AP26113 also inhibits ROS1, an actionable target to be discussed later in this review, and selectively inhibits EGFR T790M without affecting the native receptor. In a phase I/II multicenter study, 55 patients with advanced malignancies, including 47 with NSCLC refractory to available therapies, received daily doses of AP26113. Of the 24 patients who had ALK-positive solid tumors, 15 responded. Among ALK-rearranged NSCLC patients with prior crizotinib only, 12 out of 16 (75%) responded. The drug appeared to have activity in the CNS as well. Four out of 5 ALK-positive patients with untreated or progressing CNS lesions had evidence of radiographic improvement in the CNS, including 1 patient resistant to both crizotinib and LDK378. The most common adverse events were fatigue (40%), nausea (36%), and diarrhea (33%), generally at CTCAE grade 1/2.
A third ALK inhibitor in development is alectinib, previously known as CH/RO5424802. In a phase I/II study of 58 patients with ALK-rearranged NSCLC and no prior ALK inhibitor therapy, the overall response rate for alectinib in 46 patients on the phase II part of the study was 93.5% (95%CI: 82.1-98.6) with 2 CRs and 41 PRs. With a median follow-up period of 12.6 mo, 47 out of 58 patients were still on study treatment, and the median treatment duration had passed 10.3 mo. Alectinib has been shown to have activity post crizotinib as well. In a phase I study of alectinib in 37 patients with ALK-rearranged NSCLC who progressed after crizotinib and chemotherapy, partial response (PR) was observed in 48% of all patients and 59.5% of the subgroup of patients receiving doses of 460 mg or higher twice a day. Median PFS had not been reached, with the median duration on study ranging from 39 d to over 347 d. Sixteen of these ALK-rearranged NSCLC patients had CNS metastases. Although PFS had not been reached by June 2013, alectinib demonstrated rapid benefit in brain metastases in a number of patients, including those resistant to crizotinib. The most common side effects of the drug were fatigue, myalgia, cough, liver enzyme elevation, peripheral edema and rash[86,87].
There are also other second-generation ALK inhibitors in earlier stages of clinical development. For example, X-396, a potent and highly specific ALK TKI, demonstrated preclinical activity against the most common ALK fusions as well as against secondary ALK mutations that conferred resistance to crizotinib. X-396 is currently in phase I development (ClinicalTrials.gov identifier NCT01625234). PF-06463922 is a promising next-generation ALK/ROS1 inhibitor that has potent and selective inhibitory activity against all known acquired crizotinib-resistant mutations. PF-06463922 is also capable of penetrating the blood brain barrier in preclinical animal models. The drug is also currently in phase I development (ClinicalTrials.gov identifier NCT01970865). ASP3026 is another potent ALK inhibitor that also has activity against crizotinib-resistant tumors in mouse model. ASP3026 is currently in phase I development (ClinicalTrials.gov identifier NCT01401504).
OTHER “ACTIONABLE” MOLECULAR TARGETS
The discovery of the oncogenic alterations involving EGFR and ALK and their inhibitors has revolutionized the treatment of non-small cell lung cancer over the past decade. However, EGFR-mutant and ALK-rearranged cancers make up less than one-fifth of all NSCLC cases in the United States. Several other potentially actionable molecular targets have recently been found.
ROS1 gene rearrangements, involving the receptor tyrosine kinase ROS1 and partners CD74, SLC24A2, and FIG, are the driver oncogenes in a small subset of NSCLC[91-93] also responsive to crizotinib. An expansion cohort of the phase I crizotinib study PROFILE 1001 included 40 patients with ROS1-positive NSCLC. In the 35 patients who were evaluated, the ORR was 60% with 2 complete response (CR), 19 PR, and 10 stable disease (SD) cases. Six-month PFS probability was 76% (95%CI: 55-88). Median PFS had not been reached when the results were reported at the World Conference on Lung Cancer in October 2013. Unfortunately, acquired resistance to crizotinib in ROS1-positive patients has also been reported. A patient with the ROS1-CD74 fusion oncogene initially responded dramatically to two mo of crizotinib treatment but then progressed in the third month. Her tumor was found to have a novel G2032R mutation in the CD74-ROS1 fusion junction that had not been observed before crizotinib treatment. Recently a promising ROS1 inhibitor, foretinib, has been shown to demonstrate efficacy against ROS1-rearranged tumor cells, including crizotinib-resistant cells. Foretinib, which also inhibits other kinases including MET and VEGFR2, is being studied in phase I and II studies in a variety of cancers.
About 1% to 2% of NSCLC tumors have mutations in HER2 exon 20[96,97], which is not clearly associated with HER2 amplification. Although anti-Her2 therapies are ineffective in HER2-amplified NSCLC[98,99], HER2-mutant NSCLC has been shown to be responsive to trastuzumab plus chemotherapy, with an overall response rate of 50% and median PFS of 5.1 mo in one case series. Afatinib, the ErbB family inhibitor approved for EGFR-mutant NSCLC as discussed earlier in this review, also has clinical activity against HER2-mutant NSCLC in a small case series[96,100]. As HER family members signal via the PI3K-AKT-mTOR cascade, recent attempts have been made to inhibit both HER2 and mTOR in HER2-driven cancers. In a phase I study of the combination of neratinib (a small molecule pan-HER inhibitor) and temsirolimus (an mTOR inhibitor), 7 patients with HER2-mutant NSCLC were treated, with 2 showing partial responses. An ongoing phase II study compares neratinib vs neratinib plus temsirolimus in patients with HER2-mutant NSCLC (ClinicalTrials.gov identifier NCT01827267).
BRAF activating mutations can be observed in 1%-3% of NSCLC[102,103]. In one case series, about half of these BRAF mutations are the V600E mutation that is also seen in melanoma. Unlike EGFR, ALK, and ROS1 genetic alterations that are associated with light or never smoking status, BRAF mutations in NSCLC are often reported in current or former smokers. In a phase II study, 17 patients with BRAF V600E-mutant NSCLC received dabrafenib, which had previously shown activity in BRAF V600E-mutant melanoma. Seven patients out of 13 (54%) evaluable patients had PR, with 1 patient having stable disease. The drug was generally well tolerated, and the median duration of treatment was 9 wk, with the longest duration of response being 49 wk when the results were reported at the 2013 ASCO Annual Meeting. An ongoing phase II study tests dabrafenib vs dabrafenib and trametinib, an inhibitor of MEK that is downstream of BRAF, in patients with BRAF V600E mutation-positive NSCLC (ClinicalTrials.gov identifier NCT01336634).
Other rare genetic alterations in NSCLC have been found and have potentially therapeutic agents include MET amplification, FGFR1 amplification, RET translocations, and MEK1 mutations. Investigations using inhibitors of these oncogenic pathways are ongoing, with anecdotal responses reported in some cases. A detailed discussion of these targets is beyond the scope of this review. Table 1 summarizes the targeted therapies for NSCLC that have already been approved or are still in ongoing clinical trials.
Table 1 Selected current targeted therapies for non-small cell lung cancer and their stages of development.
Until several years ago, the only therapeutic option for advanced NSCLC was cytotoxic chemotherapy. The discovery of activating EGFR mutations and the unprecedented efficacy of erlotinib and gefitinib in EGFR-mutant NSCLC ushered in an era of truly personalized cancer care. There is increasing evidence that targeted therapies yield better outcomes than traditional chemotherapy in appropriate patients. The Lung Cancer Mutation Consortium recently reported that an actionable driver was detected in 64% of patients with pulmonary adenocarcinoma and that among the 938 patients the consortium tracked, the median survival was 3.5 years for the 264 with an oncogenic driver treated with genotype-directed therapy, 2.4 years for the 318 with an oncogenic driver with no genotype-directed therapy, and 2.1 years for the 360 with no driver identified (P < 0.0001).
With the advance of next-generation sequencing, one can foresee a future in which every single tumor will be sequenced at the time of diagnosis to find potential driver mutations that can be therapeutically targeted. While some rare patients have had astounding disease remission, defined as long-term complete responses to EGFR TKI therapy[106,107], these patients are still usually receiving active therapy and therefore cannot truly be considered “cured”. Therefore, challenges remain on how to overcome the seemingly inevitable acquired resistance to these therapies. The optimal sequence for the use of multiple inhibitors of the same target and the efficacy and tolerability of combinations of inhibitors of various oncogenic pathways are being actively studied. In addition, the emerging promise of immunotherapies such as PD-1/PDL-1 directed antibody therapy opens the door for studies of potential synergy with these drugs and tyrosine kinase targeted therapeutics. Even if a cure for advanced lung cancer still remains out of reach, one can hope that in the near future advanced NSCLC may be controlled like other chronic diseases with well-tolerated and effective therapies.
P- Reviewer: He XY, Okuma Y, Rosell R, Zhang YJ S- Editor: Wen LL L- Editor: A E- Editor: Zhang DN
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics.CA Cancer J Clin. 2011;61:69-90.
Schiller JH, Harrington D, Belani CP, Langer C, Sandler A, Krook J, Zhu J, Johnson DH. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer.N Engl J Med. 2002;346:92-98.
Rusch V, Klimstra D, Venkatraman E, Pisters PW, Langenfeld J, Dmitrovsky E. Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression.Clin Cancer Res. 1997;3:515-522.
Brabender J, Danenberg KD, Metzger R, Schneider PM, Park J, Salonga D, Hölscher AH, Danenberg PV. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer Is correlated with survival.Clin Cancer Res. 2001;7:1850-1855.
Pérez-Soler R, Chachoua A, Hammond LA, Rowinsky EK, Huberman M, Karp D, Rigas J, Clark GM, Santabárbara P, Bonomi P. Determinants of tumor response and survival with erlotinib in patients with non--small-cell lung cancer.J Clin Oncol. 2004;22:3238-3247.
Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].J Clin Oncol. 2003;21:2237-2246.
Kris MG, Natale RB, Herbst RS, Lynch TJ, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.JAMA. 2003;290:2149-2158.
Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R. Erlotinib in previously treated non-small-cell lung cancer.N Engl J Med. 2005;353:123-132.
Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, Thongprasert S, Tan EH, Pemberton K, Archer V. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer).Lancet. 2005;366:1527-1537.
Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.N Engl J Med. 2004;350:2129-2139.
Paez JG, Jänne PA, Lee JC, Tracy S, Greulich H, Gabriel S, Herman P, Kaye FJ, Lindeman N, Boggon TJ. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.Science. 2004;304:1497-1500.
Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, Singh B, Heelan R, Rusch V, Fulton L. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib.Proc Natl Acad Sci USA. 2004;101:13306-13311.
Ji H, Li D, Chen L, Shimamura T, Kobayashi S, McNamara K, Mahmood U, Mitchell A, Sun Y, Al-Hashem R. The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies.Cancer Cell. 2006;9:485-495.
Politi K, Zakowski MF, Fan PD, Schonfeld EA, Pao W, Varmus HE. Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.Genes Dev. 2006;20:1496-1510.
Sequist LV, Bell DW, Lynch TJ, Haber DA. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.J Clin Oncol. 2007;25:587-595.
Rosell R, Moran T, Queralt C, Porta R, Cardenal F, Camps C, Majem M, Lopez-Vivanco G, Isla D, Provencio M. Screening for epidermal growth factor receptor mutations in lung cancer.N Engl J Med. 2009;361:958-967.
D’Angelo SP, Pietanza MC, Johnson ML, Riely GJ, Miller VA, Sima CS, Zakowski MF, Rusch VW, Ladanyi M, Kris MG. Incidence of EGFR exon 19 deletions and L858R in tumor specimens from men and cigarette smokers with lung adenocarcinomas.J Clin Oncol. 2011;29:2066-2070.
Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, Sunpaweravong P, Han B, Margono B, Ichinose Y. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.N Engl J Med. 2009;361:947-957.
Fukuoka M, Wu YL, Thongprasert S, Sunpaweravong P, Leong SS, Sriuranpong V, Chao TY, Nakagawa K, Chu DT, Saijo N. Biomarker analyses and final overall survival results from a phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS).J Clin Oncol. 2011;29:2866-2874.
Pham D, Kris MG, Riely GJ, Sarkaria IS, McDonough T, Chuai S, Venkatraman ES, Miller VA, Ladanyi M, Pao W. Use of cigarette-smoking history to estimate the likelihood of mutations in epidermal growth factor receptor gene exons 19 and 21 in lung adenocarcinomas.J Clin Oncol. 2006;24:1700-1704.
Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, Ahn MJ, Yun T, Ahn JS, Suh C. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung.J Clin Oncol. 2012;30:1122-1128.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.Lancet Oncol. 2010;11:121-128.
Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Seto T, Satouchi M, Tada H, Hirashima T, Asami K. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib (G) with cisplatin plus docetaxel (CD) as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermal growth fa.J Clin Oncol. 2012;30 suppl:abstr 7521.
Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, Gemma A, Harada M, Yoshizawa H, Kinoshita I. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR.N Engl J Med. 2010;362:2380-2388.
Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, Zhang S, Wang J, Zhou S, Ren S. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study.Lancet Oncol. 2011;12:735-742.
Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.Lancet Oncol. 2012;13:239-246.
Zhou C, Wu YL, Liu X, Wang C, Chen G, Feng JF, Zhang S, Wang J, Zhou S, Ren S. Overall survival (OS) results from OPTIMAL (CTONG0802), a phase III trial of erlotinib (E) vs carboplatin plus gemcitabine (GC) as first-line treatment for Chinese patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC).J Clin Oncol. 2012;30 suppl:abstr 7520.
Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, Padera RF, Shapiro GI, Baum A, Himmelsbach F. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.Oncogene. 2008;27:4702-4711.
Miller VA, Hirsh V, Cadranel J, Chen YM, Park K, Kim SW, Zhou C, Su WC, Wang M, Sun Y. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.Lancet Oncol. 2012;13:528-538.
Sequist LV, Yang JC, Yamamoto N, O’Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations.J Clin Oncol. 2013;31:3327-3334.
Wu YL, Zhou C, Hu CP, Feng J, Lu S, Huang Y, Li W, Hou M, Shi JH, Lee KY. Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.Lancet Oncol. 2014;15:213-222.
Yang JCH, Sequist LV, Geater SL. Activity of afatinib in uncommon epidermal growth factor receptor (EGFR) mutations: Findings from three trials of afatinib in EGFR mutation-positive lung cancer.J Thorac Oncol. 2013;8:abstr O03.05.
Kobayashi S, Boggon TJ, Dayaram T, Jänne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.N Engl J Med. 2005;352:786-792.
Pao W, Miller VA, Politi KA, Riely GJ, Somwar R, Zakowski MF, Kris MG, Varmus H. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.PLoS Med. 2005;2:e73.
Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.Cancer Res. 2005;65:7096-7101.
Costa C, Molina MA, Drozdowskyj A, Giménez-Capitán A, Bertran-Alamillo J, Karachaliou N, Gervais R, Massuti B, Wei J, Moran T. The impact of EGFR T790M mutations and BIM mRNA expression on outcome in patients with EGFR-mutant NSCLC treated with erlotinib or chemotherapy in the randomized phase III EURTAC trial.Clin Cancer Res. 2014;20:2001-2010.
Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, Lindeman N, Gale CM, Zhao X, Christensen J. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.Science. 2007;316:1039-1043.
Bean J, Brennan C, Shih JY, Riely G, Viale A, Wang L, Chitale D, Motoi N, Szoke J, Broderick S. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib.Proc Natl Acad Sci USA. 2007;104:20932-20937.
Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, Chiang A, Yang G, Ouerfelli O, Kris MG. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors.Clin Cancer Res. 2006;12:6494-6501.
Bean J, Riely GJ, Balak M, Marks JL, Ladanyi M, Miller VA, Pao W. Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.Clin Cancer Res. 2008;14:7519-7525.
Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations.PLoS Med. 2007;4:1669-1679; discussion 1680.
Ohashi K, Sequist LV, Arcila ME, Moran T, Chmielecki J, Lin YL, Pan Y, Wang L, de Stanchina E, Shien K. Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.Proc Natl Acad Sci USA. 2012;109:E2127-E2133.
Takezawa K, Pirazzoli V, Arcila ME, Nebhan CA, Song X, de Stanchina E, Ohashi K, Janjigian YY, Spitzler PJ, Melnick MA. HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutation.Cancer Discov. 2012;2:922-933.
Katakami N, Atagi S, Goto K, Hida T, Horai T, Inoue A, Ichinose Y, Koboyashi K, Takeda K, Kiura K. LUX-Lung 4: a phase II trial of afatinib in patients with advanced non-small-cell lung cancer who progressed during prior treatment with erlotinib, gefitinib, or both.J Clin Oncol. 2013;31:3335-3341.
Campbell A, Reckamp KL, Camidge DR, Giaccone G, Gadgeel SM, Khuri FR, Engelman JA, Denis LJ, O’Connell JP, Janne PA. PF-00299804 (PF299) patient (pt)-reported outcomes (PROs) and efficacy in adenocarcinoma (adeno) and nonadeno non-small cell lung cancer (NSCLC): A phase (P) II trial in advanced NSCLC after failure of chemotherapy (CT) and erlotinib (E).ASCO Meeting Abstracts. 2010;28:7596.
Sequist LV, Besse B, Lynch TJ, Miller VA, Wong KK, Gitlitz B, Eaton K, Zacharchuk C, Freyman A, Powell C. Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.J Clin Oncol. 2010;28:3076-3083.
Pietanza MC, Lynch TJ, Lara PN, Cho J, Yanagihara RH, Vrindavanam N, Chowhan NM, Gadgeel SM, Pennell NA, Funke R. XL647--a multitargeted tyrosine kinase inhibitor: results of a phase II study in subjects with non-small cell lung cancer who have progressed after responding to treatment with either gefitinib or erlotinib.J Thorac Oncol. 2012;7:219-226.
Janjigian YY, Azzoli CG, Krug LM, Pereira LK, Rizvi NA, Pietanza MC, Kris MG, Ginsberg MS, Pao W, Miller VA. Phase I/II trial of cetuximab and erlotinib in patients with lung adenocarcinoma and acquired resistance to erlotinib.Clin Cancer Res. 2011;17:2521-2527.
Janjigian YY, Groen HJ, Horn L, Smit EF, Fu F, Wang F, Shahidi M, Denis LJ, Pao W, Miller VA. Activity and tolerability of combined EGFR targeting with afatinib (BIBW 2992) and cetuximab in T790M non-small cell lung cancer patients. 2011;.
Wakelee HA, Gettinger SN, Engelman JA, Janne PA, West HJ, Subramaniam DS, Leach JW, Wax MB, Yaron Y, Jr PL. A phase Ib/II study of XL184 (BMS 907351) with and without erlotinib (E) in patients (pts) with non-small cell lung cancer (NSCLC).ASCO Meeting Abstracts. 2010;28:3017.
Giaccone G, Camidge DR, Jänne PA. Combined pan-ERBB and ALK/ROS1/MET inhibition with dacomitinib and crizotinib in advanced non-small cell lung cancer (NSCLC): update of a phase I trial.J Thorac Oncol. 2013;8:abstr MO07.07.
Zhou W, Ercan D, Chen L, Yun CH, Li D, Capelletti M, Cortot AB, Chirieac L, Iacob RE, Padera R. Novel mutant-selective EGFR kinase inhibitors against EGFR T790M.Nature. 2009;462:1070-1074.
Soria JC, Sequist LV, Gadgeel S. First-In-Human Evaluation of CO-1686, an Irreversible, Highly, Selective Tyrosine Kinase Inhibitor of Mutations of EGFR (Activating and T790M).J Thorac Oncol. 2013;8:abstr O03.06.
Ranson M, Pao W, Kim DW. AZD9291: an irreversible, potent and selective tyrosine kinase inhibitor (TKI) of activating (EGFRm ) and resistance (T790M) mutations in advanced NSCLC.J Thorac Oncol. 2013;8:abstr MO21.12.
Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, Fujiwara S, Watanabe H, Kurashina K, Hatanaka H. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.Nature. 2007;448:561-566.
Koivunen JP, Mermel C, Zejnullahu K, Murphy C, Lifshits E, Holmes AJ, Choi HG, Kim J, Chiang D, Thomas R. EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer.Clin Cancer Res. 2008;14:4275-4283.
Boland JM, Erdogan S, Vasmatzis G, Yang P, Tillmans LS, Johnson MR, Wang X, Peterson LM, Halling KC, Oliveira AM. Anaplastic lymphoma kinase immunoreactivity correlates with ALK gene rearrangement and transcriptional up-regulation in non-small cell lung carcinomas.Hum Pathol. 2009;40:1152-1158.
Takeuchi K, Choi YL, Soda M, Inamura K, Togashi Y, Hatano S, Enomoto M, Takada S, Yamashita Y, Satoh Y. Multiplex reverse transcription-PCR screening for EML4-ALK fusion transcripts.Clin Cancer Res. 2008;14:6618-6624.
Wong DW, Leung EL, So KK, Tam IY, Sihoe AD, Cheng LC, Ho KK, Au JS, Chung LP, Pik Wong M. The EML4-ALK fusion gene is involved in various histologic types of lung cancers from nonsmokers with wild-type EGFR and KRAS.Cancer. 2009;115:1723-1733.
Inamura K, Takeuchi K, Togashi Y, Nomura K, Ninomiya H, Okui M, Satoh Y, Okumura S, Nakagawa K, Soda M. EML4-ALK fusion is linked to histological characteristics in a subset of lung cancers.J Thorac Oncol. 2008;3:13-17.
Takeuchi K, Choi YL, Togashi Y, Soda M, Hatano S, Inamura K, Takada S, Ueno T, Yamashita Y, Satoh Y. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer.Clin Cancer Res. 2009;15:3143-3149.
Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, Nardone J, Lee K, Reeves C, Li Y. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.Cell. 2007;131:1190-1203.
Takahashi T, Sonobe M, Kobayashi M, Yoshizawa A, Menju T, Nakayama E, Mino N, Iwakiri S, Sato K, Miyahara R. Clinicopathologic features of non-small-cell lung cancer with EML4-ALK fusion gene.Ann Surg Oncol. 2010;17:889-897.
Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, Solomon B, Stubbs H, Admane S, McDermott U. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.J Clin Oncol. 2009;27:4247-4253.
Christensen JG, Zou HY, Arango ME, Li Q, Lee JH, McDonnell SR, Yamazaki S, Alton GR, Mroczkowski B, Los G. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma.Mol Cancer Ther. 2007;6:3314-3322.
Wass M, Behlendorf T, Schädlich B, Mottok A, Rosenwald A, Schmoll HJ, Jordan K. Crizotinib in refractory ALK-positive diffuse large B-cell lymphoma: a case report with a short-term response.Eur J Haematol. 2014;92:268-270.
Butrynski JE, D’Adamo DR, Hornick JL, Dal Cin P, Antonescu CR, Jhanwar SC, Ladanyi M, Capelletti M, Rodig SJ, Ramaiya N. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor.N Engl J Med. 2010;363:1727-1733.
Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, Ou SH, Dezube BJ, Jänne PA, Costa DB. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.N Engl J Med. 2010;363:1693-1703.
Shaw AT, Kim DW, Nakagawa K, Seto T, Crinó L, Ahn MJ, De Pas T, Besse B, Solomon BJ, Blackhall F. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.N Engl J Med. 2013;368:2385-2394.
Park J, Yoshida K, Kondo C, Shimizu J, Horio Y, Hijioka S, Hida T. Crizotinib-induced esophageal ulceration: a novel adverse event of crizotinib.Lung Cancer. 2013;81:495-496.
Katayama R, Shaw AT, Khan TM, Mino-Kenudson M, Solomon BJ, Halmos B, Jessop NA, Wain JC, Yeo AT, Benes C. Mechanisms of acquired crizotinib resistance in ALK-rearranged lung Cancers.Sci Transl Med. 2012;4:120ra17.
Choi YL, Soda M, Yamashita Y, Ueno T, Takashima J, Nakajima T, Yatabe Y, Takeuchi K, Hamada T, Haruta H. EML4-ALK mutations in lung cancer that confer resistance to ALK inhibitors.N Engl J Med. 2010;363:1734-1739.
Doebele RC, Pilling AB, Aisner DL, Kutateladze TG, Le AT, Weickhardt AJ, Kondo KL, Linderman DJ, Heasley LE, Franklin WA. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer.Clin Cancer Res. 2012;18:1472-1482.
Kim S, Kim TM, Kim DW, Go H, Keam B, Lee SH, Ku JL, Chung DH, Heo DS. Heterogeneity of genetic changes associated with acquired crizotinib resistance in ALK-rearranged lung cancer.J Thorac Oncol. 2013;8:415-422.
Shaw AT, Mehra R, Kim DW, Felip E, Chow LQM, Camidge DR, Tan DSW, Vansteenkiste JF, Sharma S, De Pas T. Clinical activity of the ALK inhibitor LDK378 in advanced, ALK-positive NSCLC.ASCO Meeting Abstracts. 2013;31:8010.
Katayama R, Khan TM, Benes C, Lifshits E, Ebi H, Rivera VM, Shakespeare WC, Iafrate AJ, Engelman JA, Shaw AT. Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.Proc Natl Acad Sci USA. 2011;108:7535-7540.
Ceccon M, Mologni L, Bisson W, Scapozza L, Gambacorti-Passerini C. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.Mol Cancer Res. 2013;11:122-132.
Camidge DR, Bazhenova L, Salgia R, Weiss GJ, Langer CJ, Shaw AT, Narasimhan NI, Dorer DJ, Rivera VM, Zhang J. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results.ASCO Meeting Abstracts. 2013;31:8031.
Camidge DR, Bazhenova L, Salgia R. Updated results of a first-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies.J Thorac Oncol. 2013;8:abstr MO07.06.
Nakagawa K, Kiura K, Nishio M, Seto T, Maemondo M, Inoue A, Hida T, Yamamoto N, Yoshioka H, Harada M. A phase I/II study with a highly selective ALK inhibitor CH5424802 in ALK-positive non-small cell lung cancer (NSCLC) patients: Updated safety and efficacy results from AF-001JP.ASCO Meeting Abstracts. 2013;31:8033.
Gadgeel S, Ou SH, Chiappori AA. A phase 1 dose escalation study of a new ALK inhibitor, CH5424802/RO5424802, in ALK Non-Small Cell Lung Cancer (NSCLC) patients who have failed crizotinib.J Thorac Oncol. 2013;8:abstr O16.06.
Ou SHI, Gadgeel S, Chiappori AA. Consistent therapeutic efficacy of CH5424802/RO5424802 in brain metastases among crizotinib-refractory ALK-positive non-small cell lung cancer (NSCLC) patients in an ongoing phase I/II study (AF-002JG/NP28761, NCT01588028).J Thorac Oncol. 2013;8:abstr O16.07.
Lovly CM, Heuckmann JM, de Stanchina E, Chen H, Thomas RK, Liang C, Pao W. Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors.Cancer Res. 2011;71:4920-4931.
Zou HY, Engstrom LR, Li Q. PF-06463922, a novel brain-penetrating small molecule inhibitor of ALK/ROS1 with potent activity against a broad spectrum of ALK resistant mutations in preclinical models in vitro and in vivo.Mol Cancer Ther. 2013;12:Abstr C253.
Mori M, Ueno Y, Konagai S, Fushiki H, Shimada I, Kondoh Y, Saito R, Mori K, Shindou N, Soga T. The selective anaplastic lymphoma receptor tyrosine kinase inhibitor ASP3026 induces tumor regression and prolongs survival in non-small cell lung cancer model mice.Mol Cancer Ther. 2014;13:329-340.
Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, Massion PP, Siwak-Tapp C, Gonzalez A, Fang R. ROS1 rearrangements define a unique molecular class of lung cancers.J Clin Oncol. 2012;30:863-870.
Rimkunas VM, Crosby KE, Li D, Hu Y, Kelly ME, Gu TL, Mack JS, Silver MR, Zhou X, Haack H. Analysis of receptor tyrosine kinase ROS1-positive tumors in non-small cell lung cancer: identification of a FIG-ROS1 fusion.Clin Cancer Res. 2012;18:4449-4457.
Chin LP, Soo RA, Soong R, Ou SH. Targeting ROS1 with anaplastic lymphoma kinase inhibitors: a promising therapeutic strategy for a newly defined molecular subset of non-small-cell lung cancer.J Thorac Oncol. 2012;7:1625-1630.
Ou SHI, Kim DW, Camidge DR. Crizotinib therapy for patients with advanced ROS1-rearranged non-small cell lung cancer.J Thorac Oncol. 2013;8:abstr MO07.03.
Awad MM, Katayama R, McTigue M, Liu W, Deng YL, Brooun A, Friboulet L, Huang D, Falk MD, Timofeevski S. Acquired resistance to crizotinib from a mutation in CD74-ROS1.N Engl J Med. 2013;368:2395-2401.
Mazières J, Peters S, Lepage B, Cortot AB, Barlesi F, Beau-Faller M, Besse B, Blons H, Mansuet-Lupo A, Urban T. Lung cancer that harbors an HER2 mutation: epidemiologic characteristics and therapeutic perspectives.J Clin Oncol. 2013;31:1997-2003.
Arcila ME, Chaft JE, Nafa K, Roy-Chowdhuri S, Lau C, Zaidinski M, Paik PK, Zakowski MF, Kris MG, Ladanyi M. Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas.Clin Cancer Res. 2012;18:4910-4918.
Gatzemeier U, Groth G, Butts C, Van Zandwijk N, Shepherd F, Ardizzoni A, Barton C, Ghahramani P, Hirsh V. Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.Ann Oncol. 2004;15:19-27.
Zinner RG, Glisson BS, Fossella FV, Pisters KM, Kies MS, Lee PM, Massarelli E, Sabloff B, Fritsche HA, Ro JY. Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpressing disease.Lung Cancer. 2004;44:99-110.
De Grève J, Teugels E, Geers C, Decoster L, Galdermans D, De Mey J, Everaert H, Umelo I, In’t Veld P, Schallier D. Clinical activity of afatinib (BIBW 2992) in patients with lung adenocarcinoma with mutations in the kinase domain of HER2/neu.Lung Cancer. 2012;76:123-127.
Gandhi L, Bahleda R, Tolaney SM, Kwak EL, Cleary JM, Pandya SS, Hollebecque A, Abbas R, Ananthakrishnan R, Berkenblit A. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors.J Clin Oncol. 2014;32:68-75.
Sequist LV, Heist RS, Shaw AT, Fidias P, Rosovsky R, Temel JS, Lennes IT, Digumarthy S, Waltman BA, Bast E. Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice.Ann Oncol. 2011;22:2616-2624.
Paik PK, Arcila ME, Fara M, Sima CS, Miller VA, Kris MG, Ladanyi M, Riely GJ. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations.J Clin Oncol. 2011;29:2046-2051.
Planchard D, Mazieres J, Riely GJ, Rudin CM, Barlesi F, Quoix EA, Souquet PJ, Socinski MA, Switzky J, Ma B. Curtis M, Streit MRW, Johnson BE. Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E mutation-positive non-small cell lung cancer (NSCLC) patients.ASCO Meeting Abstracts. 2013;31:8009.
Kris MG, Johnson B, Berry L. Treatment with therapies matched to oncogenic drivers improves survival in patients with lung cancers: results from the Lung Cancer Mutation Consortium (LCMC).J Thorac Oncol. 2013;8:abstr PL03.07.
Hata Y, Takai Y, Takahashi H, Takagi K, Isobe K, Hasegawa C, Shibuya K, Goto H, Tamaki K, Sato F. Complete response of 7 years’ duration after chemoradiotherapy followed by gefitinib in a patient with intramedullary spinal cord metastasis from lung adenocarcinoma.J Thorac Dis. 2013;5:E65-E67.
Matsuzaki T, Terashima T, Ogawa R, Naitou A, Miyauchi J, Morishita T. [A case of advanced adenocarcinoma of the lung which maintained complete response for 5 years by treatment with gefitinib].Nihon Kokyuki Gakkai Zasshi. 2010;48:600-603.